Zhang YJ - Search Results

1

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial.

Gui YZ, Wang W, Wu QQ, Ding QC, Qian HJ, Lu QB, Zhang YJ, Zhuang YL, Deng L, Zuo YL, Luo L, Jia JY. Gui YZ, et al. Among authors: zhang yj. Front Pharmacol. 2024 Jun 12;15:1359939. doi: 10.3389/fphar.2024.1359939. eCollection 2024. Front Pharmacol. 2024. PMID: 38933676 Free PMC article.

2

Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers.

Zhao N, Xie R, Zhao X, Zhao H, Jia B, Zhang Y, Luo L, Huang Z, Li J, Wang X, Yan H, He B, Xie H, Ren Q, Cui Y. Zhao N, et al. Clin Drug Investig. 2019 Jul;39(7):671-681. doi: 10.1007/s40261-019-00791-8. Clin Drug Investig. 2019. PMID: 31079356

3

A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers.

Zhao N, Jia B, Zhao H, Xu J, Sheng X, Luo L, Huang Z, Wang X, Ren Q, Zhang Y, Zhao X, Cui Y. Zhao N, et al. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01686-19. doi: 10.1128/AAC.01686-19. Print 2019 Dec 20. Antimicrob Agents Chemother. 2019. PMID: 31636065 Free PMC article. Clinical Trial.

4

Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection.

Guan XD, Tang XG, Zhang YJ, Xie HM, Luo L, Wu D, Chen R, Hu P. Guan XD, et al. Among authors: zhang yj. Front Pharmacol. 2021 Jan 28;11:617122. doi: 10.3389/fphar.2020.617122. eCollection 2020. Front Pharmacol. 2021. PMID: 33584296 Free PMC article.

5

Physiologically-based pharmacokinetic modeling predicts the drug interaction potential of GLS4 in co-administered with ritonavir.

Sun Z, Zhao N, Xie R, Jia B, Xu J, Luo L, Zhuang Y, Peng Y, Liu X, Zhang Y, Zhao X, Liu Z, Cui Y. Sun Z, et al. CPT Pharmacometrics Syst Pharmacol. 2024 Sep;13(9):1503-1512. doi: 10.1002/psp4.13184. Epub 2024 Jun 20. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 39031849 Free PMC article.

6

Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus.

Zhang H, Zhu X, Li X, Chen H, Wu M, Li C, Liu J, Liu C, Zhang Y, Ding Y. Zhang H, et al. Diabetes Obes Metab. 2020 Feb;22(2):191-202. doi: 10.1111/dom.13887. Epub 2019 Nov 5. Diabetes Obes Metab. 2020. PMID: 31588657 Clinical Trial.

7

Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis.

Rao H, Yang X, Tan Y, Ning Q, Yang D, Wang J, Yang Y, Zheng S, Yang D, Hou J, Xie Q, Zhao C, Zhang L, Mao X, Sun T, Bai L, Zhang F, Jin J, Zhao Y, Wang M, Xie W, Ma Y, Quan J, Yan X, An P, Lin F, Jia J, Hu X, Gong Z, Wu J, Chen Y, Jia Z, Lin M, Wang G, Zhu Y, Zhang Y, Xie H, Luo L, Ren Q, Huang R, Wei L. Rao H, et al. J Clin Transl Hepatol. 2020 Sep 28;8(3):255-261. doi: 10.14218/JCTH.2020.00031. Epub 2020 Sep 11. J Clin Transl Hepatol. 2020. PMID: 33083247 Free PMC article.

8

Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges.

Li M, Wang Q, Li Y, Cao S, Zhang Y, Wang Z, Liu G, Li J, Gu B. Li M, et al. Pharmacol Ther. 2020 Aug;212:107539. doi: 10.1016/j.pharmthera.2020.107539. Epub 2020 Mar 20. Pharmacol Ther. 2020. PMID: 32201314 Review.

9

Antiviral Activity and Pharmacokinetics of the Hepatitis B Virus (HBV) Capsid Assembly Modulator GLS4 in Patients With Chronic HBV Infection.

Zhang H, Wang F, Zhu X, Chen Y, Chen H, Li X, Wu M, Li C, Liu J, Zhang Y, Ding Y, Niu J. Zhang H, et al. Clin Infect Dis. 2021 Jul 15;73(2):175-182. doi: 10.1093/cid/ciaa961. Clin Infect Dis. 2021. PMID: 32649736 Free PMC article. Clinical Trial.

10

Corrigendum to "Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: Current and future challenges" [Pharmacology & Therapeutics 212 (2020) 107539].

Li M, Wang Q, Li Y, Cao S, Zhang Y, Wang Z, Liu G, Li J, Gu B. Li M, et al. Pharmacol Ther. 2022 Jun;234:108184. doi: 10.1016/j.pharmthera.2022.108184. Epub 2022 Apr 15. Pharmacol Ther. 2022. PMID: 35437152 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,665 results

Search Page

Filters